EI-Emshaty Hoda M, Gadelhak Seham A, Abdelaziz Mohamed M, Abbas Ayman T, Gadelhak Nabil A
Hepatogastroenterology. 2014 Sep;61(134):1688-95.
BACKGROUND/AIMS: P53 gene mutations have a higher malignant potential and often leads to the production of p53 Abs. This study was conducted to evaluate the clinical implications of p53Abs in HCV-related HCC and its diagnostic capacity as a new biomarker in HCC.
83 patients with HCV-chronic liver disease (25 with LC and 58 with HCC) were enrolled in this study. Ten healthy individuals (HI) served as control group. The studied group was subjected to clinical examination, imaging radiology, laboratory investigation and liver biopsy. Serum p53 Abs was assessed by (ELISA).
Serum p53 Abs in HCC (0.5567±0.227) was significantly elevated (p<0.0001) than LC (0.252±0.0099) and HI (0.214±0.068) (p=0.001). Serum P53 Abs was significantly (p=0.01) increased with the progression of child score but there was no significant difference with regard to age, sex, tumor size or serum liver profile. However, serum p53 Abs showed no significant positive correlation with AFP in HCV-related HCC (r=0.09, p value= 0.6) but serum p53 Abs in combination with AFP showed higher diagnostic sensitivity (82.2%) of HCC than either alone.
P53 Abs could be regarded as a specific biomarker for cancer process and its use in combination with AFP may increase the diagnostic sensitivity of HCC.
背景/目的：p53基因突变具有较高的恶性潜能，常导致p53抗体产生。本研究旨在评估p53抗体在丙型肝炎病毒相关肝癌中的临床意义及其作为肝癌新生物标志物的诊断能力。
本研究纳入83例丙型肝炎病毒慢性肝病患者（25例肝硬化患者和58例肝癌患者）。10名健康个体作为对照组。研究组接受临床检查、影像放射学检查、实验室检查和肝活检。采用酶联免疫吸附测定法（ELISA）评估血清p53抗体。
肝癌患者血清p53抗体（0.5567±0.227）显著高于肝硬化患者（0.252±0.0099）和健康个体（0.214±0.068）（p<0.0001）（p=0.001）。血清p53抗体随Child评分进展显著升高（p=0.01），但在年龄、性别、肿瘤大小或血清肝功能指标方面无显著差异。然而，在丙型肝炎病毒相关肝癌中，血清p53抗体与甲胎蛋白无显著正相关（r=0.09，p值=0.6），但血清p53抗体与甲胎蛋白联合检测对肝癌的诊断敏感性高于单独检测（82.2%）。
p53抗体可被视为癌症进程的特异性生物标志物，其与甲胎蛋白联合使用可能会提高肝癌的诊断敏感性。
